RE:RE:RE:RE:RE:RE:RE:RE:New Press Release - Theralase(R) Provides Update on Bladder Cancer Clinical StudyStevenBirch wrote: Yes an update so soon? The FDA requested a resubmission of the pre-BTD so you would think that if they clean up a couple of things that maybe THEY think BTD is in the offing. And Arkady says "This ACT technology...will be very attractive to patients & uro-oncologists (obvious) AND the insurance companies that insure these patients".
Every update exudes more confidence including their ability to commercialize their technology!
Oilminerdeluxe wrote: Something must be behind this release. I didn't think we would see anything until the next Q report. Always happy too see updates. Perhaps JV negotiations as you say, or a boring but needed PP? We will see. That BTD would be soooo nice to have in the pocket. Perhaps the pre-application thing is very close now at least.
Thank you StevenBirch that is more than likely one of the points outlined by the FDA what we saw and read in today's update. Exactly a clear patient update with current data numbers for the new Pre-BTD, sometimes people just can't see what's right there in front of them. My bet today's update was part of the FDA’s request.
Might I also say to those who are trying to inject fear by suggesting another financial raise that in any business strategy once they start releasing many News Releases in short time lapses its a buildup to very powerful announcements. No financial needs currently as the January 9th 50 cent warrants will give them 2 million into their coffers. The way I see it volume will increase progressively over the next few weeks and months along with the share price & warrants to $3 -$5 by 2023 year end.